| ID | 1103 |
| Name of the vaccine | Euvichol |
| Microbe | Bacteria |
| Disease name | Cholera |
| Name of bacteria | Vibrio cholerae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | Over 1 year |
| Description of the vaccine | Cholera vaccine containing O1 and O139 of Vibrio cholerae. |
| Name of the manufacturer | EuBiologics Co., Ltd. |
| Name of the manufacturing country | South Korea |
| Year of manufacture | 2014 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension |
| Dosage | Two doses of vaccine at an interval of two weeks. |
| Mechanism of action | NA |
| Route of administration | Oral |
| Indications | NA |
| Export | NA |
| Approval | Korean Ministry of Food and Drug Safety export license (2014) and WHO pre-qualified (2015) |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Headache, fever, diarrhoea, nausea and myalgia. |
| Post vaccination | Medical supervision for at least 30 minutes after vaccination. |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31879125 |
| Clinical trial number | NA |
| Reference | http://www.eubiologics.com/en/products/Euvichol_insert.pdf |
| Other name | NA |
| Additional Links | NA
|